Behçet's ileocolitis: successful treatment with tumor necrosis factor-alpha antibody (infliximab) therapy: report of a case

Michael T Kram; Louis D May; Stephen Goodman; Sharon Molinas

doi:10.1007/s10350-004-6506-4

Behçet's ileocolitis: successful treatment with tumor necrosis factor-alpha antibody (infliximab) therapy: report of a case

Dis Colon Rectum. 2003 Jan;46(1):118-21. doi: 10.1007/s10350-004-6506-4.

Authors

Michael T Kram¹, Louis D May, Stephen Goodman, Sharon Molinas

Affiliation

¹ Department of Gastroenterology, Nyack Hospital, New York, USA.

PMID: 12544532
DOI: 10.1007/s10350-004-6506-4

Abstract

Behçet's disease is a chronic inflammatory disease characterized by recurrent oral aphthae and systemic manifestations. Gastrointestinal involvement is rare. We report a case of ileocolitis secondary to Behçet's successfully treated with tumor necrosis factor-alpha antibody (infliximab) therapy. To our knowledge this is the second reported case of Behçet's ileocolitis successfully treated with anti-tumor necrosis factor therapy.

Publication types

Case Reports

MeSH terms

Adult
Antibodies, Monoclonal / therapeutic use*
Behcet Syndrome / drug therapy*
Behcet Syndrome / pathology
Colitis / drug therapy*
Colitis / pathology
Colonoscopy
Female
Gastrointestinal Agents / therapeutic use*
Humans
Ileitis / drug therapy*
Ileitis / pathology
Infliximab
Tumor Necrosis Factor-alpha / immunology*

Substances

Antibodies, Monoclonal
Gastrointestinal Agents
Tumor Necrosis Factor-alpha
Infliximab